Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma

Fineline Cube Apr 15, 2026
Company Deals

UCB Secures EU Approval for Kygevvi as First-Ever Treatment for Ultra-Rare TK2 Deficiency

Fineline Cube Apr 15, 2026
Company Deals

Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal

Fineline Cube Apr 15, 2026
Company Deals

Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate

Fineline Cube Apr 15, 2026
Company Deals

WinHealth Pharma Licenses World’s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment

Fineline Cube Apr 14, 2026
Policy / Regulatory

FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing

Fineline Cube Apr 15, 2026
Company Drug

Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication

Fineline Cube Apr 15, 2026
Company Drug

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Fineline Cube Apr 15, 2026
Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Fineline Cube Feb 11, 2026

SciClone Pharmaceuticals Inc. (HKG: 6600) announced that the National Medical Products Administration (NMPA) has accepted for...

Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Fineline Cube Feb 11, 2026

Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture, has closed a RMB 500 million (USD 72.34 million)...

Company Drug

Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication

Fineline Cube Feb 11, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA)...

Company Drug

Takeda’s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist

Fineline Cube Feb 11, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

GSK’s RSV Vaccine Filing Accepted by NMPA for China Market Entry

Fineline Cube Feb 11, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the Center for Drug Evaluation (CDE) of China’s NMPA...

Company Deals

uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases

Fineline Cube Feb 11, 2026

uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership...

Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026

The U.S. Food and Drug Administration (FDA) announced decisive regulatory action to restrict GLP-1 active...

Policy / Regulatory

China’s NHSA Launches Reference Drug Pre-Communication System to Streamline Reimbursement Pathway

Fineline Cube Feb 11, 2026

The National Healthcare Security Administration (NHSA) has released the “Reference Drugs Pre-communication Measures (Trial)”, establishing...

Company

AstraZeneca Reports 8% Revenue Growth to $58.7 Billion in 2025; Oncology Leads with 17% Surge

Fineline Cube Feb 11, 2026

AstraZeneca PLC (AZ, NASDAQ: AZN) delivered strong 2025 financial results, with total revenues rising 8% year-on-year...

Company

Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%

Fineline Cube Feb 11, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) announced fourth quarter and full-year 2025 financial results, with total revenues...

Company Drug

Pfizer’s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections

Fineline Cube Feb 11, 2026

Pfizer Inc. (NYSE: PFE) announced that the National Medical Products Administration (NMPA) has approved an indication...

Company Drug

Eli Lilly’s Omvoh Wins NMPA Approval for Crohn’s Disease and Ulcerative Colitis in China

Fineline Cube Feb 11, 2026

The National Medical Products Administration (NMPA) has approved Eli Lilly and Company’s (NYSE: LLY) Omvoh (mirikizumab),...

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026

China Resources Pharmaceutical Group Co., Ltd. (HKG: 3320) announced plans to sell a 17.87% stake in...

Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Fineline Cube Feb 11, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience...

Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Fineline Cube Feb 11, 2026

Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...

Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026

Hangzhou Tangji Medical Technology Co., Ltd. has filed its IPO prospectus with the Hong Kong...

Company Drug

Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China

Fineline Cube Feb 11, 2026

Eisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced that the Biologics License Application (BLA) for...

Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) has entered a multi-year strategic agreement with Iambic Therapeutics,...

Company Deals

Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China

Fineline Cube Feb 10, 2026

Hemony Pharmaceutical Co., Ltd. has entered a strategic partnership with Insud Pharma, a leading Spanish...

Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Fineline Cube Feb 10, 2026

Overseas Pharmaceuticals Ltd (OPL), a China-based specialty pharmaceutical company, has entered a product development and...

Posts pagination

1 … 28 29 30 … 651

Recent updates

  • Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma
  • UCB Secures EU Approval for Kygevvi as First-Ever Treatment for Ultra-Rare TK2 Deficiency
  • Eli Lilly Restructures China Cardiometabolic Division Ahead of Foundayo Oral GLP-1 Launch
  • Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication
  • Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma

Company Deals

UCB Secures EU Approval for Kygevvi as First-Ever Treatment for Ultra-Rare TK2 Deficiency

Company

Eli Lilly Restructures China Cardiometabolic Division Ahead of Foundayo Oral GLP-1 Launch

Company Drug

Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.